AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia

FMS-like Tyrosine Kinase 3 (FLT3) mutation is associated with poor survival in acute myeloid leukemia (AML). The specific Anexelekto/MER Tyrosine Kinase (AXL) inhibitor, ONO-7475, kills FLT3-mutant AML cells with targets including Extracellular- signal Regulated Kinase (ERK) and Myeloid Cell Leukem...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	Sean M. Post, Huaxian Ma, Prerna Malaney, Xiaorui Zhang, Marisa J.L. Aitken, Po Yee Mak, Vivian R. Ruvolo, Tomoko Yasuhiro, Ryohei Kozaki, Lauren E. Chan, Lauren B. Ostermann, Marina Konopleva, Bing Z. Carter, Courtney DiNardo, Michael D. Andreeff, Joseph D. Khoury, Peter P. Ruvolo
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2021-11-01
Online Access:	https://haematologica.org/article/view/10444